Eli Lilly
American pharmacist, Union Army officer, businessman, philanthropist
Positive
Negative
Entity sentiment
Reports
News
Opinions
Statements
Articles
Relations
business May 28, 2026, 12:45 PM
CVS Caremark reinstates coverage for Zepbound after patient protests - CVS Caremark will resume coverage of Zepbound on October 1, 2026, after removing it last year.
- The decision was influenced by patient backlash and a class action lawsuit regarding the removal.
- The reinstatement of Zepbound will affect millions and may lower out-of-pocket costs for some patients.
100
science Mar 12, 2026, 10:53 AM
Eli Lilly warns about dangers of compounded weight-loss drugs - Eli Lilly found significant levels of a dangerous impurity in compounded medications containing vitamin B12 and tirzepatide.
- The company has initiated legal proceedings against various compounding entities for marketing unauthorized versions of its drugs.
- Eli Lilly calls for a nationwide recall and warns that compounded products may not be safe for consumers.
100
business Mar 9, 2026, 10:17 PM
Eli Lilly warns some Medicare patients could face higher costs for weight-loss drugs - Eli Lilly announced that under a new CMS coverage model, the expected monthly cap for weight-loss drugs may not apply to all beneficiaries.
- Some basic Medicare Part D plans may not comply with the $50 out-of-pocket limit set for GLP-1 medications.
- Lilly is committed to educating patients and physicians to help ensure access to medications at the lowest costs.
100
technology Feb 23, 2026, 2:09 PM
Eli Lilly introduces Zepbound KwikPen for weight loss treatment - Eli Lilly's Zepbound KwikPen provides a month of treatment in a single device.
- Patients can choose between the KwikPen and single-dose vials for $299 per month.
- The introduction of the KwikPen aims to enhance convenience and choice for weight loss treatment.
100
business Jan 29, 2026, 10:59 PM
Eli Lilly invests $3.5 billion to expand manufacturing in Pennsylvania - Eli Lilly develops a new $3.5 billion manufacturing facility in Fogelsville, Pennsylvania.
- The facility aims to produce injectable drugs, including unreleased weight-loss medication.
- This expansion highlights Eli Lilly's strategy of increasing domestic production to meet rising medication demand.
300
science Dec 11, 2025, 12:23 PM
Eli Lilly's drug helps patients achieve drastic weight loss and pain relief - Eli Lilly's retatrutide drug aids patients in losing approximately 28.7% of their body weight during a trial.
- The Phase 3 trial results demonstrated significant pain relief in osteoarthritis patients, with pain reduced by 75.8%.
- The promising results position Eli Lilly's retatrutide as a key player in the weight-loss market and raise hopes for individuals with obesity and related conditions.
100
business Dec 1, 2025, 2:43 PM
Eli Lilly lowers weight loss drug prices to expand access - Eli Lilly announced price cuts for Zepbound to improve patient access.
- The updated pricing includes a reduction to $299 for self-pay patients and lower prices for other dosages.
- The move highlights the competitive nature of the weight loss drug market and aims to eliminate barriers for patients.
100
science Nov 24, 2025, 8:00 AM
Eli Lilly's experimental drug eloralintide shows promising weight loss results - Eli Lilly's trial for eloralintide involved 263 adults and showed weight loss of up to 20%
- Participants also showed improvements in waist circumference, blood pressure, and other health markers
- Experts urge cautious optimism as the drug has not yet received FDA approval and highlights the importance of lifestyle changes alongside medication
100
technology Nov 19, 2025, 1:00 AM
Eli Lilly partners with Nvidia for AI-driven drug discovery breakthrough - Eli Lilly collaborates with Nvidia to enhance drug discovery through AI.
- Johnson & Johnson also partners with Nvidia to improve surgical planning.
- These partnerships highlight a broader trend of using AI in healthcare and drug research.
100
2026 All rights reserved
2026 All rights reserved